-
-
-
-
-
-
-
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
-
-
-
-
-
-
-
Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K
-
-
-
-
-
-
-
Liminal BioSciences (LMNL) Provides Update on Progress on BLA for Ryplazim, FDA Assigns PDUFA Target Action Date of March 5
-
-
-
-
-
15,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

